Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials

Background Although reversal of pretransplant renal dysfunction in hepatorenal syndrome reduces post‐transplant complications, the overall impact on morbidity and mortality requires clarification.

[1]  S. Sarin,et al.  An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response noradrenaline versus terlipressin in the treatment of HRS-1 , 2008 .

[2]  A. Sanyal,et al.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.

[3]  F. Fabrizi,et al.  Meta‐analysis: terlipressin therapy for the hepatorenal syndrome , 2006, Alimentary pharmacology & therapeutics.

[4]  N. Stockbridge,et al.  Blood pressure as an example of a biomarker that functions as a surrogate , 2006, The AAPS Journal.

[5]  J. Vinel,et al.  Treatment of Hepatorenal Syndrome as Defined by the International Ascites Club by Albumin and Furosemide Infusion According to the Central Venous Pressure: A Prospective Pilot Study , 2005, The American Journal of Gastroenterology.

[6]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[7]  R. MacLaren,et al.  Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  F. Wong,et al.  Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome , 2004, Hepatology.

[9]  C. Broelsch,et al.  Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. , 2004, European journal of medical research.

[10]  K. Demır,et al.  Terlipressin and albumin combination treatment in hepatorenal syndrome. , 2003, Hepato-gastroenterology.

[11]  M. Lafortune,et al.  Octreotide in hepatorenal syndrome: A randomized, double‐blind, placebo‐controlled, crossover study , 2003, Hepatology.

[12]  A. M. Solyman,et al.  Role of therlipressine and octreotide in type I hepatorenal syndrome (HRS) , 2003 .

[13]  D. Chelãrescu,et al.  Propranolol administration on post surgical infections in cirrhotic patients , 2003 .

[14]  E. Esrailian,et al.  Octreotide/midodrine therapy significantly improves survival in type 1 hepatorenal syndrome: Analysis of 53 treated patients & 21 controls , 2003 .

[15]  A. M. Solyman,et al.  Essential systemic hypertension and viral chronic liver disease , 2003 .

[16]  T. Sauerbruch,et al.  Vasoactive treatment of hepatorenal syndrome type 1 (HRS1) with midodrine, octreotide and albumin , 2003 .

[17]  D. Chelãrescu,et al.  Captopril in low dose associated with octreotide in hepatorenal syndrome: A randomized study , 2003 .

[18]  R. Gupta,et al.  Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial , 2003, Journal of gastroenterology and hepatology.

[19]  D. Fish,et al.  Assessing renal function in cirrhotic patients: problems and pitfalls. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  F. Roudot-thoraval,et al.  Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study , 2002, Hepatology.

[21]  I. Colle,et al.  Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis , 2002, Journal of gastroenterology and hepatology.

[22]  G. Constantinescu,et al.  Reversal of type I hepatorenal syndrome (HRS) with therlipressine and octreotide , 2002 .

[23]  R. Moreau,et al.  Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. , 2002, Gastroenterology.

[24]  W. Jiménez,et al.  Effects of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A phase II study , 2002 .

[25]  Ľ. Beňa,et al.  Hepatorenal syndrome type 1 in patients with acute alcoholic hepatitis treated with continual terlipressin infusion in combination with albumin plasmaexpansion , 2002 .

[26]  P. Fiévet,et al.  Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study* , 2002, European journal of gastroenterology & hepatology.

[27]  J. Mauillon,et al.  Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? , 2000, American Journal of Gastroenterology.

[28]  R. Bataller,et al.  Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. , 2000, Journal of hepatology.

[29]  A. Gerbes,et al.  Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine , 1999, Hepatology.

[30]  M. Prados,et al.  Response and progression in recurrent malignant glioma. , 1999, Neuro-oncology.

[31]  G. Guyatt,et al.  Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. , 1999, JAMA.

[32]  Y. Baruch,et al.  Low‐dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end‐stage heart failure , 1999, Journal of internal medicine.

[33]  R. Orlando,et al.  Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. , 1999, Clinical nephrology.

[34]  P. Angeli,et al.  Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide , 1999, Hepatology.

[35]  A. Burroughs,et al.  Improvement in renal function in hepatorenal syndrome with N-acetylcysteine , 1999, The Lancet.

[36]  L. Legault,et al.  Glomerular filtration rate measurement in cirrhotic patients with renal failure. , 1998, Clinical nephrology.

[37]  O. Bulbena,et al.  Effect of Subcutaneous Administration of Octreotide on Endogenous Vasoactive Systems and Renal Function in Cirrhotic Patients with Ascites , 1998, Digestive Diseases and Sciences.

[38]  E. Casiglia,et al.  Acute effects of the oral administration of midodrine, an α‐adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites , 1998, Hepatology.

[39]  R. Moreau,et al.  Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome , 1998, Journal of hepatology.

[40]  W. Jiménez,et al.  Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion , 1998, Hepatology.

[41]  S. Nasraway,et al.  Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. , 1997, Clinical nephrology.

[42]  R. Moreau,et al.  Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. , 1997, Journal of hepatology.

[43]  Richard Sylvester,et al.  Analysis and presentation , 1997 .

[44]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[45]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[46]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[47]  G. Klintmalm,et al.  IMPACT OF PRETRANSPLANT RENAL FUNCTION ON SURVIVAL AFTER LIVER TRANSPLANTATION , 1995, Transplantation.

[48]  P. Angeli,et al.  Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. , 1994, Archives of internal medicine.

[49]  G. Jennings,et al.  Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. , 1993, Gastroenterology.

[50]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[51]  R Simon,et al.  Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. , 1992, Journal of the National Cancer Institute.

[52]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[53]  S. Ellenberg.  Surrogate end points in clinical trials. , 1991, BMJ.

[54]  J. Ruskin,et al.  The cardiac arrhythmia suppression trial (CAST). , 1989, The New England journal of medicine.

[55]  D. V. van Thiel,et al.  Effects of renal impairment on liver transplantation. , 1987, Gastroenterology.

[56]  A. Arieff,et al.  Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. , 1987, The American journal of medicine.

[57]  T. Starzl,et al.  Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. , 1973, The New England journal of medicine.

[58]  R. Moreau.  The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. , 2004, Journal of hepatology.

[59]  M. Navasa,et al.  Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. , 2004, Journal of hepatology.

[60]  M. Voiculescu,et al.  224 Association of a selective endothelin-a receptor antagonist (ET-A RA) could improve the outcome of patients with hepatorenal syndrome (HRS) , 2004 .

[61]  O. Moine,et al.  Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. , 2001, Acta gastro-enterologica Belgica.

[62]  C. Chagneau,et al.  Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. , 1999, Journal of hepatology.

[63]  A. J. Man in 't Veld.  Surrogate end points in clinical trials. , 1997, Blood pressure. Supplement.